U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07815223) titled 'A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC' on Sept. 07.
Brief Summary: This prospective, single-arm, phase II study aims to evaluate the efficacy and safety of tislelizumab plus anlotinib as consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC) who have not progressed following concurrent or sequential chemoradiotherapy.
Study Start Date: Nov. 04, 2025
Study Type: INTERVENTIONAL
Condition:
SCLC, Limited Stage
Intervention:
DRUG: Tislelizumab + Anlotinib
Tislelizumab 200 mg on Day 1 plus anlotinib 10 mg on Days 1-14 of each 3-week cycle.
R...